Zydus begins human trials for potential Covid-19 vaccine

ZyCoV-D, its plasmid DNA vaccine, was found to be safe, immunogenic and well-tolerated.

Indian pharmaceutical company Zydus said on Wednesday it has started human studies for its potential COVID-19 vaccine, as coronavirus infections continue to surge in the world’s third worst-hit nation.

injecting injection vaccine vaccination medicine flu man doctor insulin health drug influenza concept - stock image (HT Archive)

ZyCoV-D, its plasmid DNA vaccine, was found to be safe, immunogenic and well-tolerated in the pre-clinical toxicity studies, Zydus said.

In the human trials, Zydus will enrol over 1,000 subjects across multiple clinical study sites in India.